


Cite this: *RSC Adv.*, 2025, 15, 11354

# Explanation of the potential mechanism of *Sophora flavescens* Ait and processed products treating ulcerative colitis based on the analysis method of “chemical composition characterization-target prediction”

Xiaoting Wang,<sup>a</sup> Yue Liu,<sup>c</sup> Tianni Jiang<sup>b</sup> and Hui Gao<sup>\*b</sup>

Processing is often used to prepare decoctions of traditional Chinese medicine (TCM) with reduced toxicity and enhanced efficacy. While *Sophora flavescens* Ait (SFA) is often used directly, processing with rice-washed water (RSFA) was performed in ancient times, and processing with wheat bran (WSFA) is a more modern method. Processing has been shown to enhance the anti-inflammatory and antibacterial effects of SFA, though the mechanisms underlying this change are unclear. In this study, a total of 106 active components of SFA, RSFA, and WSFA, mostly alkaloid and flavonoid derivatives, were identified using ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry, and a total of 159 potential molecular targets in the treatment of ulcerative colitis were identified by network pharmacology. Relationships among key targets, including epidermal growth factor receptor, heat shock protein 90, SRC, and p100 $\alpha$ , were identified through development of a protein–protein interaction network. GO enrichment indicated that peptidyl-tyrosine phosphorylation, peptidyl-tyrosine modification, and cellular response to chemical stress are important in the action of SFA against ulcerative colitis, and KEGG enrichment showed that the phosphoinositide 3-kinase-AKT signaling pathway is another key target. Molecular docking showed that the active components have strong affinities for phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha and protein kinase C alpha. *In vitro* cell experiments have demonstrated that five active components in SFA can exert anti-inflammatory effects by modulating IL-6 and IL-10. We found that processing results in changes in the chemical composition of SFA that influence the treatment of UC. This study provides a reference for further research into the pharmacodynamic basis for the enhanced efficacy of processed SFA in the treatment of ulcerative colitis.

Received 1st July 2024

Accepted 1st April 2025

DOI: 10.1039/d4ra04760e

rsc.li/rsc-advances

## 1. Introduction

The clinical manifestations of ulcerative colitis (UC) include abdominal pain, diarrhea and mucopurulent and bloody stools, as well as urgency and heaviness. In traditional Chinese medicine (TCM), the specific symptoms “bloody stool” and “chronic dysentery” are both associated with UC.<sup>1</sup> Damp heat is one of the main syndromes associated with UC in TCM. Damp heat is an important factor underlying the onset and development of UC, and it is also the main factor leading to its recurrence and difficulty in treatment.<sup>2,3</sup>

TCMs are derived from plants, animals, and minerals. Many of these sources are hard and thick in texture, some contain impurities and sands, and some are associated with significant side effects when used in unprocessed forms. Accordingly, the native materials generally cannot be directly used in clinical practice and instead must be processed before application.<sup>4</sup> Many changes can occur during processing of TCM with excipients, including alterations to efficacy, flavor, and toxicity. Liquid excipients include wine, vinegar, honey, and rice-washed water, while solid excipients include wheat bran, rice, and river sand. Rice-washed water alone can invigorate qi, relieve vexation and thirst, and resolve toxins, and as an excipient, it can decrease a drug’s pungent flavor, mitigate extreme properties, and strengthen the functions of replenishing the spleen and strengthening the middle energizer. Processing the drug with wheat bran can also moderate a drug’s drastic properties and improve its therapeutic effectiveness.

<sup>a</sup>Liaoning University of Traditional Chinese Medicine, Shenyang, 110847, Liaoning, China

<sup>b</sup>School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, 116600, China. E-mail: gaohuitcm@163.com

<sup>c</sup>Liaoning Agricultural Vocational and Technical College, Yingkou, 115009, China


TCM represents a potentially useful tool in the treatment of UC. In particular, lightyellow sophora root, also known as “kushen” in China, is the dried roots of *Sophora flavescens* Ait (SFA), which is associated with both bitterness and cold and is a candidate treatment for UC due to its ability to eliminate heat and dampness, its stimulation of water excretion, its effectiveness at treating carbuncles and other types of sores, and its activity against enterorrhagia and bloody stool.<sup>5</sup> Accordingly, several processed products derived from SFA are widely used as an important component of TCM in the treatment of UC. Due to its unique manufacturing method and active ingredients, it has unique advantages in the treatment of UC. In TCM, SFA is usually used to treat heat dysentery, bloody stool, jaundice with anuria, red or white vaginal discharge, pudendal swelling and itch, eczema, dampness sore, itching of skin, scabies and tinea leprosy.<sup>6</sup> Extracts of SFA have demonstrated several pharmacological activities, including anti-inflammatory, antioxidant, and antitumor effects. Its main components, such as alkaloids and flavonoids, have activity.

The processing of SFA has been studied in depth. For example, based on ancient books, the Chinese Pharmacopoeia, and modern literature, a research group conducted a comparative study on the chemical and pharmacological properties of 8 processed products of SFA.<sup>7</sup> The results showed that processing with wheat bran to produce WSFA and with rice-washed water to produce RSFA led to significant changes to the activities of SFA, and the products exhibited stronger anti-inflammatory and antibacterial effects *in vitro* and stronger anti-UC effects *in vivo* than did the raw products, supporting the rationality of the historical use of WSFA and RSFA. The study also found that some components of SFA undergo transformations during the processing, leading to changes in their amounts. On this basis, we speculate that the enhanced therapeutic effect of processed SFA may be related to changes to the molecular composition of these materials. At present, however, few reports have investigated the mechanisms of SFA or its processed products in treating UC by combining the pharmacological components of SFA after processing with target prediction.<sup>8</sup>

The integration of network pharmacology and molecular docking methods can serve as an alternative to screening compounds before animal experiments. It focuses on the interaction between components and target proteins, providing strong support for elucidating the “multi-component, multi-target” nature of TCM.<sup>9,10</sup> In this study, we performed a UPLC-Q-TOF-MS/MS-based analysis of the chemical composition of SFA and its processed products. The resulting information, combined with network pharmacology analysis of the correlation between targets, disease, and drugs, allowed a preliminary verification of the material basis and possible molecular mechanisms involved in the treatment of UC by SFA and its processed products. In addition, an *in silico* molecular docking analysis provided a theoretical basis for further research on the synergistic mechanisms underlying the clinical treatment of UC by SFA and its processed products.

## 2. Materials and methods

### 2.1. Identification of the chemical constituents in SFA and the processed products by UPLC-Q-TOF-MS/MS

**2.1.1 Materials and reagents.** *Sophora flavescens* Ait. was purchased from Sichuan Xinhehua Co., Ltd (Chengdu, China) and authenticated by Professor Haibo Yin (College of Pharmacy, Liaoning University of Chinese Medicine). All voucher specimens were deposited at the authors' laboratory. LC-MS grade acetonitrile and formic acid were purchased from Merck KGaA (Darmstadt, Germany). All other reagents were analytical grade and obtained from Tianjin Kermol Chemical Reagent Co., Ltd (Tianjin, China). Reference standards of matrine, oxymatrine, sophoridine, formononetin were obtained from Dalian Meilun Biological Technology Co., Ltd (Dalian, China), and the reference standard of kushenol I was obtained from Sichuan Wei-keqi Biological Technology Co., Ltd (Chengdu, China). The purity of each compound was determined to be  $\geq 98\%$ . Ultra-pure water was prepared with a Milli-Q water purification system (Millipore, Billerica, MA, USA).

**2.1.2 Sample preparation.** In order to prepare stir-fried SFA with wheat bran, wheat bran was placed in a pot and heated until smoke emerged. SFA decoction pieces were added to the mixture and then removed when the surface was yellow or deep yellow. The wheat bran was removed by sifting, and the decoction pieces were allowed to cool to room temperature.

To prepare processed SFA with rice-washed water, SFA decoction pieces were soaked with rice-washed water overnight at room temperature ( $25 \pm 5^\circ\text{C}$ ).<sup>11</sup> The pieces were removed, rinsed twice with clean water, and steamed for 8 h. The processed decoction pieces were dried in the sun, crushed, and sifted through a No. 4 sieve.

**2.1.3. Qualitative analysis by UPLC-Q-TOF-MS/MS.** Chromatographic separation of SFA components was achieved on an Acquity UPLC BEH C18 column (100 mm  $\times$  2.1 mm, 1.7  $\mu\text{m}$ ) maintained at  $35^\circ\text{C}$ . Data acquisition and instrument control were accomplished using MassLynx 4.1 software (Waters Corp., MA, USA). The mobile phase consisted of a mixture of water containing 0.1% formic acid (A) and acetonitrile (B). The elution gradient profile was 0 to 1 min, 98% A; 1 to 4 min, 98 to 80% A; 4 to 15 min, 80 to 60% A; 15 to 17 min, 60 to 50% A; 17 to 20 min, 50 to 48% A; 20 to 26 min, 48 to 32% A; 26 to 29 min, 32 to 16% A; and 29 to 31 min, 16 to 10% A. The flow rate was 0.4 mL min<sup>-1</sup>.

The Waters Xevo G2-XS system (Waters Corp., MA, USA), capable of performing electrospray ionization (ESI), was used in positive and negative ionization modes. High purity N<sub>2</sub> was used as an auxiliary spray ionization and desolvation gas: N<sub>2</sub> temperature,  $450^\circ\text{C}$ ; desolvating nitrogen flow rate, 800 L h; taper hole counter blowing nitrogen, 50 L h; capillary ionization voltage, 3 kV; and full scan range, 100–1500 *m/z*.

**2.1.4. Identification of ingredients.** Information regarding the chemical composition of SFA was obtained by searching UNIFI databases (Waters Corp., Milford, MA, USA). The chemical composition of SFA was matched, and the accurate fragmentations (*m/z*) of  $[\text{M} + \text{H}]^+$ ,  $[\text{M} + \text{Na}]^+$  in the positive ion mode

and  $[M-H]^-$ ,  $[M + HCOO]^-$  in the negative ion mode were selected to provide a reference for analysis and identification. The compounds were confirmed through mass spectrometry analysis and comparison with related reference substances.

## 2.2. Network pharmacology analysis

**2.2.1 Target identifying and prediction.** Potential targets were identified and predicted through chemical ingredients screened by UPLC mass spectrum, retrieved from the Traditional Chinese Medicine Systems Pharmacology database (TCMSP, <https://tcmspw.com/tcmsp.php>). These compounds were converted into canonical SMILES query using the PubChem database. SwissTargetPrediction (<http://www.swisstargetprediction.ch/>) was utilized to predict molecular targets of SFA based on the canonical SMILES structures and specifying the species *Homo sapiens*. Genes encoding potential UC-related targets were identified using the GeneCards server. The intersection of the group of proteins identified as potential targets of SFA with the group of gene products identified from the GeneCards analysis was visualized using Draw Venn Diagram (<https://bioinfogp.cnb.csic.es/tools/venny/index.html>), and this intersection was considered to contain potential pharmacodynamic targets.

**2.2.2 Protein–protein interaction network construction.** The proteins in the intersection of SFA targets and UC-related gene products were analyzed for imported into the STRING resource (<https://string-db.org/>) to obtain protein–protein interaction (PPI) relationships. The results were introduced

into Cytoscape 3.7.2 software to obtain a PPI network and to analyze the network topology and identify core targets.

**2.2.3 Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses.** RStudio was employed to perform GO and KEGG enrichment analyses to clarify the biological significance of the network of targets. The GO analysis included three aspects: biological process, molecular function, and cellular component. The Pathview and GOpot packages in RStudio were used to visualize the GO interactive network and KEGG pathways, respectively.

## 2.3 Molecular docking

Computer-assistant molecular docking technology was utilized to investigate the physical interactions between SFA compounds and their targets. The 10 most significant ingredients were selected as ligands to analyze against their respective potential pharmacodynamic targets. The SDF files of these 10 compounds were downloaded from the PubChem database (<https://pubchem.ncbi.nlm.nih.gov/>) and converted to three-dimensional structures using Chem3D (22.0, PerkinElmer informatics Inc). The molecular structures of target proteins were obtained from the Protein Data Bank (PDB, <http://www.rcsb.org/>). Discover Studio 2019 was used for molecular docking, and RStudio was used to sort the interaction strengths by binding free energy.


## 2.4 Molecular dynamics simulation

The complex was analyzed *via* 100 ns MD simulations using Gromacs 2023. The protein was modeled with CHARMM 36 force field parameters, while the ligand topology was generated using GAFF2 force field parameters. The protein–ligand complex is placed in a cubic box with periodic boundary conditions, and the box is filled with water molecules using the TIP3P water model. Electrostatic interactions are handled using Particle Mesh Ewald and the Verlet algorithm. Subsequently, we performed 100 000 steps of isothermal isovolumetric ensemble equilibrium followed by isothermal isobaric ensemble equilibrium, utilizing a coupling constant of 0.1 ps and a simulation duration of 100 ps. Both van der Waals and Coulomb interactions were computed using a cutoff distance of 1.0 nm. Finally, the system underwent molecular dynamics simulation using Gromacs 2023, maintaining a constant temperature of 300 K and a constant pressure of 1 bar, with a total simulation duration of 100 ns.

## 2.5 In vitro cell experiments

**2.5.1 Cell culture.** RAW264.7 cells are a mouse macrophage cell line derived from the Dalian Bergolin Biotechnology Co., Ltd (Dalian, China). RAW264.7 cells were cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin–streptomycin at 37 °C in a humidified environment containing 5% CO<sub>2</sub>. Cells in the logarithmic growth phase, achieving approximately 80% confluency, were utilized for subsequent experiments.

**2.5.2 Cell viability assay.** RAW264.7 cells were seeded in a 96-well plate at a density of  $5 \times 10^4$  cells per well, with 100  $\mu$ L



**Fig. 1** The total ion chromatograms of SFA, WSFA, and RSFA by UPLC-Q-TOF-MS/MS (from top to bottom). (A) TIC of SFA and WSFA in positive ion mode, (B) TIC of SFA and WSFA in negative ion mode. (C) TIC of SFA and RSFA in positive ion mode, (D) TIC of SFA and RSFA in negative ion mode.

Table 1 The compounds in SFAs and its processed products

| No. | $t_{R/min}$ | Components                              | Chemical formula     | Ion mode                   | $m/z$   | Source |      |      |
|-----|-------------|-----------------------------------------|----------------------|----------------------------|---------|--------|------|------|
|     |             |                                         |                      |                            |         | SFA    | WSFA | RSFA |
| 1   | 1.78        | Baptifoline                             | $C_{15}H_{20}N_2O_2$ | $[M + H]^+$                | 261.15  | +      | +    | +    |
| 2   | 2.96        | Kaempferol                              | $C_{15}H_{10}O_6$    | $[M + H]^+$                | 287.05  | +      | +    | +    |
| 3   | 3.88        | Isokuraramine                           | $C_{12}H_{18}N_2O_2$ | $[M + H]^+$                | 223.14  | +      | +    | +    |
| 4   | 4.04        | Cytisine                                | $C_{11}H_{14}N_2O$   | $[M + H]^+$                | 191.11  | +      | +    | +    |
| 5   | 4.19        | Anagryne                                | $C_{15}H_{20}N_2O$   | $[M + H]^+$                | 245.16  | +      | +    | +    |
| 6   | 4.49        | Oxysophocarpine                         | $C_{15}H_{22}N_2O_2$ | $[M + H]^+$                | 263.17  | +      | —    | +    |
| 7   | 4.55        | Isomatrine                              | $C_{15}H_{24}N_2O$   | $[M + H]^+$                | 249.19  | +      | +    | —    |
| 8   | 4.70        | Umbelliferone                           | $C_9H_6O_3$          | $[M + H]^+$                | 163.03  | +      | +    | +    |
| 9   | 4.83        | Isosophocarpine                         | $C_{15}H_{22}N_2O$   | $[M + H]^+$                | 247.18  | +      | +    | +    |
| 10  | 4.88        | 7,11-Dehydromatrine                     | $C_{15}H_{22}N_2O$   | $[M + H]^+$ , $[M + Na]^+$ | 247.18  | +      | +    | +    |
| 11  | 4.97        | 2,4-Dihydroxybenzoic acid               | $C_7H_6O_4$          | $[M + H]^+$                | 155.03  | +      | +    | +    |
| 12  | 5.02        | 13,14-Dehydrosophoridine                | $C_{15}H_{22}N_2O$   | $[M + H]^+$                | 247.18  | +      | +    | +    |
| 13  | 5.08        | N-Methylcytisine                        | $C_{12}H_{16}N_2O$   | $[M + H]^+$                | 205.13  | +      | +    | +    |
| 14  | 5.20        | Lupanine                                | $C_{15}H_{24}N_2O$   | $[M + H]^+$                | 249.19  | +      | +    | +    |
| 15  | 5.37        | Lehmannine                              | $C_{15}H_{22}N_2O$   | $[M + H]^+$ , $[M + Na]^+$ | 247.18  | +      | —    | +    |
| 16  | 5.48        | Mamanine                                | $C_{15}H_{22}N_2O_2$ | $[M + H]^+$                | 263.17  | +      | +    | +    |
| 17  | 5.51        | Rhombifoline                            | $C_{15}H_{20}N_2O$   | $[M + H]^+$                | 245.16  | +      | +    | +    |
| 18  | 5.57        | Oxymatrine                              | $C_{15}H_{24}N_2O_2$ | $[M + H]^+$                | 265.19  | +      | +    | +    |
| 19  | 5.69        | Matrine                                 | $C_{15}H_{24}N_2O$   | $[M + H]^+$                | 249.19  | +      | +    | +    |
| 20  | 6.02        | Glabrol                                 | $C_{25}H_{28}O_4$    | $[M + H]^+$                | 393.20  | +      | +    | +    |
| 21  | 6.07        | Sophoranol N-oxide                      | $C_{15}H_{24}N_2O_3$ | $[M + H]^+$ , $[M + Na]^+$ | 281.18  | +      | +    | +    |
| 22  | 6.15        | Sophoranol                              | $C_{15}H_{24}N_2O_2$ | $[M + H]^+$                | 265.19  | +      | +    | +    |
| 23  | 6.19        | Sophoramine                             | $C_{15}H_{20}N_2O$   | $[M + H]^+$                | 245.16  | —      | +    | —    |
| 24  | 6.29        | Rutin                                   | $C_{27}H_{30}O_{16}$ | $[M + Na]^+$ , $[M + H]^+$ | 633.14  | +      | —    | —    |
| 25  | 6.47        | 12 $\alpha$ -Hydroxysophocarpine        | $C_{15}H_{22}N_2O_2$ | $[M + H]^+$ , $[M + Na]^+$ | 263.17  | +      | +    | +    |
| 26  | 6.58        | Isorhamnetin-3-O- $\beta$ -rutinoside   | $C_{28}H_{32}O_{16}$ | $[M + H]^+$                | 625.17  | +      | +    | +    |
| 27  | 7.05        | Kosamol A                               | $C_{30}H_{38}O_8$    | $[M + H]^+$                | 527.26  | +      | +    | +    |
| 28  | 7.13        | Biochanin A                             | $C_{16}H_{12}O_5$    | $[M + H]^+$                | 285.07  | +      | +    | +    |
| 29  | 7.47        | Kushenol S                              | $C_{20}H_{20}O_5$    | $[M + H]^+$                | 341.13  | +      | +    | +    |
| 30  | 7.58        | Resokaempferol                          | $C_{15}H_{10}O_5$    | $[M + H]^+$                | 271.06  | +      | +    | +    |
| 31  | 8.20        | Kushenol J                              | $C_{27}H_{32}O_{14}$ | $[M + H]^+$                | 581.18  | +      | +    | +    |
| 32  | 8.36        | Genistein                               | $C_{15}H_{10}O_5$    | $[M + H]^+$                | 271.05  | +      | +    | +    |
| 33  | 8.53        | Kushenin                                | $C_{16}H_{14}O_5$    | $[M + H]^+$                | 287.09  | +      | +    | +    |
| 34  | 9.28        | Kushenol O                              | $C_{27}H_{30}O_{13}$ | $[M + H]^+$ , $[M + Na]^+$ | 563.17  | +      | +    | +    |
| 35  | 9.93        | Quercetin                               | $C_{15}H_{10}O_7$    | $[M + H]^+$                | 303.04  | +      | +    | —    |
| 36  | 9.95        | Kushenol V                              | $C_{21}H_{22}O_7$    | $[M + H]^+$                | 387.14  | +      | —    | +    |
| 37  | 10.03       | Kushecarpins A                          | $C_{17}H_{18}O_6$    | $[M + H]^+$                | 319.11  | —      | +    | —    |
| 38  | 10.37       | Formononetin                            | $C_{16}H_{12}O_4$    | $[M + H]^+$                | 269.08  | +      | +    | +    |
| 39  | 10.47       | Sophoraflacoside                        | $C_{59}H_{96}O_{27}$ | $[M + H]^+$ , $[M + Na]^+$ | 1237.62 | +      | +    | +    |
| 40  | 10.49       | Soyasaponin I                           | $C_{48}H_{78}O_{18}$ | $[M + H]^+$ , $[M + Na]^+$ | 943.52  | +      | +    | +    |
| 41  | 10.50       | Azukisaponin I                          | $C_{42}H_{68}O_{13}$ | $[M + H]^+$                | 781.47  | +      | +    | +    |
| 42  | 10.82       | Pterocarpin                             | $C_{17}H_{14}O_5$    | $[M + H]^+$ , $[M + Na]^+$ | 299.09  | +      | +    | +    |
| 43  | 11.05       | Kaikasaponin II                         | $C_{48}H_{78}O_{17}$ | $[M + Na]^+$ , $[M + H]^+$ | 949.51  | —      | +    | —    |
| 44  | 11.46       | Kushenol H                              | $C_{26}H_{32}O_8$    | $[M + H]^+$ , $[M + Na]^+$ | 473.21  | +      | +    | +    |
| 45  | 11.71       | 1,8-Dihydroxy-3-methylanthraquinone     | $C_{15}H_{10}O_4$    | $[M + H]^+$                | 255.06  | +      | +    | +    |
| 46  | 11.75       | Trifolirhizin                           | $C_{22}H_{22}O_{10}$ | $[M + H]^+$                | 447.12  | +      | +    | +    |
| 47  | 11.81       | Isorhamnetin                            | $C_{16}H_{12}O_7$    | $[M + H]^+$                | 317.06  | +      | +    | +    |
| 48  | 11.87       | Kushenol K                              | $C_{26}H_{32}O_8$    | $[M + H]^+$ , $[M + Na]^+$ | 473.21  | +      | +    | +    |
| 49  | 12.46       | Glucuronic acid                         | $C_6H_{10}O_7$       | $[M + H]^+$                | 195.0   | +      | +    | +    |
| 50  | 12.96       | Mackia                                  | $C_{16}H_{12}O_5$    | $[M + H]^+$ , $[M + Na]^+$ | 285.07  | +      | +    | +    |
| 51  | 13.04       | Azukisaponin V                          | $C_{48}H_{77}O_{18}$ | $[M + H]^+$                | 943.52  | +      | +    | +    |
| 52  | 14.02       | 4,7,2'-Trihydroxy-4'-methoxyisoflavanol | $C_{15}H_{12}O_6$    | $[M + H]^+$                | 289.10  | +      | +    | +    |
| 53  | 14.07       | Flavenochromane C                       | $C_{21}H_{20}O_6$    | $[M + H]^+$ , $[M + Na]^+$ | 369.13  | +      | —    | —    |
| 54  | 14.26       | Trifolirhizin 6'-monoacetate            | $C_{24}H_{25}O_{11}$ | $[M + H]^+$ , $[M + Na]^+$ | 489.13  | +      | +    | +    |
| 55  | 14.79       | Kushecarpins C                          | $C_{17}H_{16}O_7$    | $[M + Na]^+$               | 355.07  | +      | +    | +    |
| 56  | 14.97       | Kurardinol                              | $C_{26}H_{32}O_7$    | $[M + H]^+$ , $[M + Na]^+$ | 457.22  | +      | +    | +    |
| 57  | 15.02       | Noranhycaritin                          | $C_{20}H_{34}O_6$    | $[M + H]^+$ , $[M + Na]^+$ | 371.14  | +      | +    | +    |
| 58  | 15.16       | Kushenol N                              | $C_{26}H_{30}O_7$    | $[M + H]^+$ , $[M + Na]^+$ | 455.20  | +      | +    | +    |
| 59  | 15.71       | Kushenol Q                              | $C_{26}H_{32}O_7$    | $[M + H]^+$ , $[M + Na]^+$ | 457.22  | +      | +    | +    |
| 60  | 16.49       | Ethylparaben                            | $C_9H_{10}O_3$       | $[M + H]^+$                | 167.06  | +      | +    | +    |
| 61  | 17.24       | Xanthohumol                             | $C_{21}H_{22}O_5$    | $[M + H]^+$ , $[M + Na]^+$ | 355.15  | +      | +    | +    |

Table 1 (Contd.)

| No. | $t_{\text{R}}/\text{min}$ | Components                                       | Chemical formula                               | Ion mode                                               | $m/z$  | Source |      |      |
|-----|---------------------------|--------------------------------------------------|------------------------------------------------|--------------------------------------------------------|--------|--------|------|------|
|     |                           |                                                  |                                                |                                                        |        | SFA    | WSFA | RSFA |
| 62  | 17.41                     | Azukisaponin II                                  | $\text{C}_{42}\text{H}_{68}\text{O}_{14}$      | $[\text{M} + \text{H}]^+$                              | 797.46 | +      | +    | +    |
| 63  | 17.80                     | Neokurarinol                                     | $\text{C}_{27}\text{H}_{34}\text{O}_7$         | $[\text{M} + \text{H}]^+$                              | 471.23 | +      | +    | +    |
| 64  | 17.94                     | Flavenochromane B                                | $\text{C}_{25}\text{H}_{26}\text{O}_6$         | $[\text{M} + \text{H}]^+$                              | 423.17 | +      | +    | +    |
| 65  | 17.98                     | Kushenol G                                       | $\text{C}_{25}\text{H}_{28}\text{O}_8$         | $[\text{M} + \text{H}]^+$                              | 457.18 | +      | +    | +    |
| 66  | 17.99                     | Kaikasaponin III                                 | $\text{C}_{48}\text{H}_{78}\text{O}_{17}$      | $[\text{M} + \text{H}]^+$ , $[\text{M} + \text{Na}]^+$ | 949.51 | +      | +    | +    |
| 67  | 18.00                     | Kushenol T                                       | $\text{C}_{25}\text{H}_{30}\text{O}_6$         | $[\text{M} + \text{H}]^+$                              | 427.21 | +      | +    | +    |
| 68  | 18.05                     | Kushenol W                                       | $\text{C}_{21}\text{H}_{22}\text{O}_7$         | $[\text{M} + \text{H}]^+$                              | 387.14 | +      | +    | +    |
| 69  | 18.07                     | Leachianone G                                    | $\text{C}_{20}\text{H}_{20}\text{O}_6$         | $[\text{M} + \text{H}]^+$                              | 357.13 | +      | +    | +    |
| 70  | 18.09                     | 3'-Methoxydaidzein                               | $\text{C}_{16}\text{H}_{12}\text{O}_5$         | $[\text{M} + \text{H}]^+$                              | 285.07 | +      | +    | +    |
| 71  | 18.37                     | Kushenol A                                       | $\text{C}_{25}\text{H}_{28}\text{O}_5$         | $[\text{M} + \text{H}]^+$                              | 409.19 | +      | +    | +    |
| 72  | 18.41                     | Kushenol I                                       | $\text{C}_{26}\text{H}_{30}\text{O}_7$         | $[\text{M} + \text{H}]^+$ , $[\text{M} + \text{Na}]^+$ | 455.20 | +      | +    | +    |
| 73  | 18.74                     | 3,4',5-Trihydroxy-7-methoxy-8-isopentenylflavone | $\text{C}_{21}\text{H}_{20}\text{O}_6$         | $[\text{M} + \text{H}]^+$                              | 369.13 | +      | +    | +    |
| 74  | 19.12                     | Isokurarinone                                    | $\text{C}_{26}\text{H}_{30}\text{O}_6$         | $[\text{M} + \text{H}]^+$ , $[\text{M} + \text{Na}]^+$ | 439.21 | +      | +    | +    |
| 75  | 19.48                     | Kushenol P                                       | $\text{C}_{26}\text{H}_{32}\text{O}_7$         | $[\text{M} + \text{H}]^+$ , $[\text{M} + \text{Na}]^+$ | 457.22 | +      | +    | +    |
| 76  | 19.59                     | Kushenol X                                       | $\text{C}_{25}\text{H}_{28}\text{O}_7$         | $[\text{M} + \text{H}]^+$ , $[\text{M} + \text{Na}]^+$ | 441.19 | +      | +    | +    |
| 77  | 19.93                     | Kushenol L                                       | $\text{C}_{25}\text{H}_{28}\text{O}_7$         | $[\text{M} + \text{H}]^+$                              | 441.19 | +      | +    | +    |
| 78  | 20.37                     | 8-C-Prenylkaempferol                             | $\text{C}_{20}\text{H}_{18}\text{O}_6$         | $[\text{M} + \text{H}]^+$                              | 355.11 | +      | +    | +    |
| 79  | 20.60                     | Neorkurainol                                     | $\text{C}_{27}\text{H}_{34}\text{O}_7$         | $[\text{M} + \text{H}]^+$                              | 441.19 | —      | —    | +    |
| 80  | 20.74                     | Glucose                                          | $\text{C}_6\text{H}_{12}\text{O}_6$            | $[\text{M} + \text{H}]^+$                              | 181.06 | +      | —    | +    |
| 81  | 21.03                     | Kushenol R                                       | $\text{C}_{26}\text{H}_{30}\text{O}_5$         | $[\text{M} + \text{H}]^+$ , $[\text{M} + \text{Na}]^+$ | 423.21 | +      | +    | +    |
| 82  | 21.45                     | Diphenyl sulfone                                 | $\text{C}_{12}\text{H}_{10}\text{O}_2\text{S}$ | $[\text{M} + \text{H}]^+$                              | 219.04 | —      | +    | +    |
| 83  | 21.46                     | 2-Methoxykurarinone                              | $\text{C}_{27}\text{H}_{32}\text{O}_6$         | $[\text{M} + \text{H}]^+$ , $[\text{M} + \text{Na}]^+$ | 453.22 | +      | +    | +    |
| 84  | 21.97                     | Kushenol F                                       | $\text{C}_{25}\text{H}_{28}\text{O}_6$         | $[\text{M} + \text{H}]^+$                              | 425.19 | +      | +    | +    |
| 85  | 21.75                     | Kushenquinone A                                  | $\text{C}_{17}\text{H}_{22}\text{O}_4$         | $[\text{M} + \text{H}]^+$                              | 291.16 | +      | +    | +    |
| 86  | 22.08                     | Lupinifolin                                      | $\text{C}_{25}\text{H}_{26}\text{O}_5$         | $[\text{M} + \text{H}]^+$                              | 407.18 | +      | +    | +    |
| 87  | 22.33                     | Kushenol E                                       | $\text{C}_{25}\text{H}_{28}\text{O}_6$         | $[\text{M} + \text{H}]^+$                              | 425.19 | +      | +    | +    |
| 88  | 22.46                     | Isoanhyocarin                                    | $\text{C}_{22}\text{H}_{24}\text{O}_6$         | $[\text{M} + \text{H}]^+$                              | 385.16 | +      | +    | +    |
| 89  | 22.60                     | Kushenol C                                       | $\text{C}_{25}\text{H}_{26}\text{O}_7$         | $[\text{M} + \text{H}]^+$                              | 439.17 | +      | +    | +    |
| 90  | 23.00                     | Kushecarpins B                                   | $\text{C}_{18}\text{H}_{18}\text{O}_7$         | $[\text{M} + \text{Na}]^+$                             | 360.09 | +      | +    | +    |
| 91  | 24.22                     | Geranyl acetate                                  | $\text{C}_{12}\text{H}_{20}\text{O}_2$         | $[\text{M} + \text{H}]^+$                              | 197.15 | —      | +    | +    |
| 92  | 24.51                     | Isoxanthohumol                                   | $\text{C}_{21}\text{H}_{22}\text{O}_5$         | $[\text{M} + \text{H}]^+$                              | 355.15 | —      | —    | +    |
| 93  | 25.02                     | Sophoraisoflavone A                              | $\text{C}_{20}\text{H}_{16}\text{O}_6$         | $[\text{M} + \text{H}]^+$                              | 353.10 | +      | +    | +    |
| 94  | 25.44                     | Naringenin                                       | $\text{C}_{15}\text{H}_{12}\text{O}_5$         | $[\text{M} + \text{H}]^+$                              | 273.07 | —      | +    | +    |
| 95  | 26.05                     | Linolenic acid                                   | $\text{C}_{18}\text{H}_{30}\text{O}_2$         | $[\text{M} + \text{H}]^+$                              | 279.23 | +      | +    | —    |
| 96  | 26.16                     | $\beta$ -Sitosterol                              | $\text{C}_{29}\text{H}_{50}\text{O}$           | $[\text{M} + \text{Na}]^+$ , $[\text{M} + \text{H}]^+$ | 437.37 | +      | —    | —    |
| 97  | 26.29                     | Kurardin                                         | $\text{C}_{26}\text{H}_{30}\text{O}_6$         | $[\text{M} + \text{H}]^+$                              | 439.21 | +      | +    | +    |
| 98  | 26.95                     | Kushenol M                                       | $\text{C}_{30}\text{H}_{36}\text{O}_7$         | $[\text{M} + \text{H}]^+$ , $[\text{M} + \text{Na}]^+$ | 509.25 | +      | +    | +    |
| 99  | 29.50                     | Kushenol D                                       | $\text{C}_{27}\text{H}_{32}\text{O}_6$         | $[\text{M} + \text{H}]^+$ , $[\text{M} + \text{Na}]^+$ | 453.22 | +      | +    | +    |
| 100 | 29.65                     | Kushenol B                                       | $\text{C}_{30}\text{H}_{36}\text{O}_6$         | $[\text{M} + \text{H}]^+$                              | 493.25 | +      | +    | +    |
| 101 | 29.80                     | Tonkinensisol                                    | $\text{C}_{25}\text{H}_{24}\text{O}_6$         | $[\text{M} + \text{H}]^+$                              | 421.16 | +      | —    | +    |
| 102 | 29.85                     | Hexadecanoic acid                                | $\text{C}_{16}\text{H}_{32}\text{O}_2$         | $[\text{M} + \text{H}]^+$                              | 257.24 | +      | +    | +    |
| 103 | 30.12                     | Myristic acid                                    | $\text{C}_{14}\text{H}_{28}\text{O}_2$         | $[\text{M} + \text{H}]^+$                              | 229.21 | +      | —    | —    |
| 104 | 31.53                     | Sophoranodichromane B                            | $\text{C}_{25}\text{H}_{28}\text{O}_5$         | $[\text{M} + \text{H}]^+$                              | 409.19 | —      | +    | —    |
| 105 | 32.07                     | Soyasaponin III                                  | $\text{C}_{42}\text{H}_{67}\text{O}_{14}$      | $[\text{M} + \text{H}]^+$                              | 813.50 | +      | —    | —    |
| 106 | 32.55                     | Betulin                                          | $\text{C}_{30}\text{H}_{50}\text{O}_2$         | $[\text{M} + \text{H}]^+$                              | 443.38 | —      | —    | +    |

of medium added to each well. The experimental design included a blank group, a control group, and a drug administration group, each consisting of various concentrations. Each group was set up with three replicate wells and incubated for 24 h. The treatment conditions were as follows: (1) blank group: no cells were inoculated; (2) control group: cells cultured solely with culture medium; (3) matrine: cells treated with different concentrations of matrine (20, 50, and 150  $\mu\text{g}\cdot\text{mL}^{-1}$ ); (4) oxy-matrine: cells treated with various concentrations of oxymatrine (20, 50, and 150  $\mu\text{g}\cdot\text{mL}^{-1}$ ); (5) kushenol I: cells treated with different concentrations of kushenol I (20, 50, and 150

$\mu\text{g}\cdot\text{mL}^{-1}$ ); (6) formononetin: cells treated with formononetin at different concentrations (20, 50, and 150  $\mu\text{g}\cdot\text{mL}^{-1}$ ); (7) sophoridine: cells treated with various concentrations of sophoridine (20, 50, and 150  $\mu\text{g}\cdot\text{mL}^{-1}$ ). After the 24 h incubation, 10% CCK-8 solution was added to each well, followed by an additional 2 h of incubation. Absorbance was measured at 450 nm using a microplate reader.

**2.5.3 Anti inflammatory activity testing.** After the intervention, cell culture supernatants from each group were collected. The supernatants were centrifuged at 3000 rpm to remove impurities, and the supernatants were collected.



Following the instructions, the concentration of IL-6 and IL-10 in the culture medium were quantified using ELISA detection kits.

### 3. Results

#### 3.1 Identification of the chemical constituents of SFA and its processed products by UPLC-Q-TOF-MS/MS

According to the standard total ion chromatograms (TICs) of the nonvolatile ingredients extracted from SFA, RSFA, and WSFA (Fig. 1), these preparations contain multiple types of compounds. Notably, the positive ESI mode was found to be more sensitive than the negative ESI mode for detecting compounds in the SFA; therefore, the positive ion mode was chosen for component analysis (Table 1). Changes to the composition of SFA during stir-frying with wheat bran were analyzed using Masslynx V4.1 and by comparing the results to chemical in the UNIFI database. Through this analysis, a total of 106 chemical components were determined to be present in SFA both before and after processing.

**3.1.1 Identification of alkaloids.** The key components of SFA and WSFA were found to include flavonoids, alkaloids, saponins, coumarins, and other types of compounds. Specifically, we identified 20 alkaloids as the main components in the extracts of SFA and WSFA. The typical alkaloids in SFA tend to contain two nitrogen atoms, with one being an acidic amide nitrogen and the other being an alkaline nitrogen.

The identification of the alkaloids utilized the MS data, as described here for matrine and lupanine as representative compounds. The molecular ion of matrine was identified at  $m/z$  249.19  $[M + H]^+$ . The characteristic fragment ions at  $m/z$  248.18  $[M + H - H]^+$ ,  $m/z$  218.17  $[M + H - H - CH_2O]^+$ ,  $m/z$  263.13  $[M + H - CH_2O - NH_3]^+$  were also found in the MS/MS spectrum. These ions are derived from the successive loss of H,  $CH_2O$  and  $NH_3$  from the molecular ions. In addition, another ions was observed at  $m/z$  189.15; this ion resulted from the loss of  $CH_2$  and rearrangement of the product at  $m/z$  263.13. The fragmentation produced ions at  $m/z$  137.12,  $m/z$  121.10, and  $m/z$  97.08. The major fragmentation ions and the proposed fragmentation pathway of matrine are shown in Fig. 2.




Fig. 2 Proposed fragmentation patterns of matrine.




Fig. 3 Proposed fragmentation patterns of lupanine.




Fig. 4 Proposed fragmentation patterns of formononetin.




Fig. 5 Proposed fragmentation patterns of kushenol I.

The molecular ion of lupanine was observed at  $m/z$  249.19  $[M + H]^+$ . The generation of an ion observed at  $m/z$  248.18  $[M + H - 2H]^+$  was due to the loss of two  $H^+$  ions from the molecular ion. Due to their structural characteristics, the C7–17 and C9–11 rings of lupanine are prone to cleavage upon fragmentation due to the McDonnell rearrangement; two ions consistent with this cleavage were observed, at  $m/z$  151.09 and 99.10. The major fragmentation ions and the proposed fragmentation pathway of lupanine are shown in Fig. 3.

**3.1.2 Identification of flavones.** The most common chemical components identified in SFA were flavonoids, of which 62 were identified. The key feature of flavonoids is a parent nucleus that with a 2-phenyl chromone derivative. There are several categories of flavonoids, including dihydroflavones, iso-flavones, flavonols, lauranes, and chalcones.

We describe here the process of identification of formononetin, kushenol I, and trifolrhizin as representative flavonoids. The major fragment ions and the proposed fragmentation pathway of these compounds are shown in Fig. 4, 5, and 6. The molecular ion of formononetin was found at  $m/z$  269.08  $[M + H]^+$ , and formononetin yielded ions at  $m/z$  199.07  $[M + H - CH_3 - CO - CHO]^+$ ,  $m/z$  227.07  $[M + H - CH_3 - CO]^+$ , and  $m/z$  255.06  $[M + H - CH_3]^+$ , which were attributed to the successive losses of CHO and then CO from the parent compound. Fragment ions observed at  $m/z$  237.02 and 119.05 were found to have derived from a retro-Diels–Alder reaction, which is a characteristic reaction of flavonoids. The ions at  $m/z$  109.02 and 82.04 were attributed to the continuous losses of CO and in the ion at  $m/z$  237.02.

For kushenol I, the product ions at  $m/z$  440.18 and  $m/z$  437.19 were formed by the neutral losses of  $CH_3$  and  $H_2O$ , respectively, from the molecular ion  $[M + H]^+$  at  $m/z$  455.20. Similarly, the fragment ion at  $m/z$  423.18 was derived from the loss of  $CH_3$  from the product ion at  $m/z$  437.19. The product ions at  $m/z$  355.11 were attributed to the loss of  $C_5H_8$  from the fragment ion at  $m/z$  423.18. The fragment ions at  $m/z$  237.02 and 119.05, 137.06, 167.03, 206.05, and 221.08 were found to derive from the retro-Diels–Alder reaction.

The parent nucleus of trifolrhizin is different from that of ordinary flavonoids in that it cannot undergo the retro-Diels–Alder reaction and due to the presence of a glucosyl group. The molecular ion of trifolrhizin was identified at  $m/z$  447.12  $[M + H]^+$ , and a fragment ion was produced at  $m/z$  285.07  $[M + H - C_6H_{10}O_5]^+$  due to the loss of glucose. The fragment ions  $m/z$  148.05 and 163.04 in the structure of trifolrhizin were considered to be indicative of the dihydrofuran and dihydropyran rings.

**3.1.3 Multivariate analysis of compounds in SFA and its processed products.** Following preprocessing of the data, principal component analyses (PCA) were used to compare the chemical compositions of unprocessed and processed SFA. Specifically, a model developed for the comparison of compounds from SFA, WSFA, and RSFA identified in the positive ion mode, the value of  $R^2_{Xcum}$  was 0.801, and the value of  $Q^2_{cum}$  was 0.701 (Fig. 7). In comparing the compounds from SFA and the processed products as identified in the negative ion mode, the values of  $R^2_{Xcum}$  and  $Q^2_{cum}$  were 0.592 and 0.298, respectively (Fig. 7). The samples were all within a 95%




Fig. 6 Proposed fragmentation patterns of trifolrhizin.




Fig. 7 PCA score chart of SFA, WSFA, and RSFA (A: ESI<sup>+</sup> mode, B: ESI<sup>−</sup> mode).

confidence interval and thus could be subjected to subsequent multivariate statistical analyses. The clustering of quality control samples indicates good instrument precision. Each sample was concentrated in the corresponding area and could be clearly separated, indicating that there are differences in the chemical compositions among SFA, WSFA, and RSFA.

PCA analysis was conducted on SFA, WSFA, and RSFA, with orthogonal partial least squares discriminant analysis (OPLS-DA) models identified and validated through internal and external methods (Fig. 8). In the positive ion mode, the internal validation results for the SFA and WSFA showed an  $R^2Y$  of 0.998 and a  $Q^2$  of 0.979. Similarly, the internal validation results for the SFA and RSFA showed an  $R^2Y$  of 1.000 and a  $Q^2$  of 0.998. The external validation of the model comparing SFA and WSFA gave values of  $R^2$  of 0.897 and  $Q^2$  of  $-0.225$ , while the values of the model comparing *Sophora flavescens* made from SFA and RSFA were an  $R^2$  of 0.909 and a  $Q^2$  of  $-0.106$ . These results suggest that the evaluation model is reliable and effective with no overfitting. In negative ion mode, the results of internal validation of the model comparing SFA and WSFA were an  $R^2Y$  of 0.966 and a  $Q^2$  of 0.590. The internal validation results for the comparison of SFA and RSFA were  $R^2Y = 0.996$  and  $Q^2 = 0.967$ , indicating the model has good predictive ability. The results of external validation of the comparison of SFA and WSFA was  $R^2 = 0.777$  and  $Q^2 = -0.400$ , and the results of external validation of the comparison of SFA and RSFA was  $R^2 = 0.900$  and  $Q^2 = -0.0707$ . These values indicate that the evaluation model is reliable and effective, and there is no overfitting.

## 3.2 Network pharmacology analysis

### 3.2.1 Identification of targets of SFA in the treatment of UC.

Active compounds in SFA were identified by UPLC-Q-TOF-MS/MS, and TCMSP and the PubChem database were searched for potential targets of these compounds. The chemicals that compose SFA are listed in Table 2, and their chemical structures are shown in Fig. 9. Potential molecular targets of these compounds were identified using the SwissTargetPrediction resource. After removal of duplicates, a total of 319 potential targets were identified.


### 3.2.2 A protein–protein interaction network connecting the potential targets.

A list of genes of interest with respect to UC was identified by scanning the GeneCards database. The intersection of the group containing potential protein targets of SFA compounds with the group of products of UC-related genes visualized using a Venn diagram (Fig. 10a). This intersection, which represented 10 compounds and 159 protein targets, was considered to contain potential pharmacodynamic targets of SFA in the treatment of UC. The compound–target network of alkaloids and flavonoids in the treatment of UC was visualized by importing the compounds and targets into Cytoscape 3.7.2 (Fig. 10b). The overlapping targets were screened, imported into the STRING database, and processed in Cytoscape 3.7.2 to obtain a PPI network, which is shown in Fig. 10c.

### 3.2.3 Biofunctional enrichment analysis of the potential targets.

GO and KEGG enrichment analyses were performed on the 159 potential targets of SFA in the treatment of UC. As shown in Fig. 11A, a total of 24 signaling pathways were found





**Fig. 8** OPLS-DA score chart (A) and substitution test chart (B) of SFA and RSFA in ESI<sup>+</sup> mode; OPLS-DA score chart (C) and substitution test chart (D) of SFA and WSFA in ESI<sup>+</sup> mode; OPLS-DA score chart (E) and substitution test chart (F) of SFA and RSFA in ESI<sup>-</sup> mode. OPLS-DA score chart (G) and substitution test chart (H) of SFA and WSFA in ESI<sup>-</sup> mode.

Table 2 Chemical compositions of SFA

| No. | Compound           | Formula                                                       | PubChem ID |
|-----|--------------------|---------------------------------------------------------------|------------|
| C1  | Formononetin       | C <sub>16</sub> H <sub>12</sub> O <sub>4</sub>                | 5280378    |
| C2  | Isoxanthohumol     | C <sub>21</sub> H <sub>22</sub> O <sub>5</sub>                | 513197     |
| C3  | Kurarinone         | C <sub>26</sub> H <sub>30</sub> O <sub>6</sub>                | 11982640   |
| C4  | Kushenol I         | C <sub>26</sub> H <sub>30</sub> O <sub>7</sub>                | 20832634   |
| C5  | Matrine            | C <sub>15</sub> H <sub>24</sub> N <sub>2</sub> O              | 91466      |
| C6  | Oxymatrine         | C <sub>15</sub> H <sub>24</sub> N <sub>2</sub> O <sub>2</sub> | 114850     |
| C7  | Sophocarpine       | C <sub>15</sub> H <sub>22</sub> N <sub>2</sub> O              | 115269     |
| C8  | Sophoraflavanone G | C <sub>25</sub> H <sub>28</sub> O <sub>6</sub>                | 72936      |
| C9  | Sophoridine        | C <sub>15</sub> H <sub>24</sub> N <sub>2</sub> O              | 165549     |
| C10 | Trifolrhizin       | C <sub>22</sub> H <sub>22</sub> O <sub>10</sub>               | 442827     |




Fig. 9 The structure of these chemical compositions.

to be enriched in the GO analysis, and the related biological processes, cellular components, and molecular functions were ranked according to *p*-value. The potential targets were found to be mainly involved in the neuronal cell body and membrane rafts, to regulate multiple molecular functions including protein tyrosine kinase activity and protein serine/threonine kinase activity, and to participate in the biological processes peptidyl-tyrosine phosphorylation and cellular response to chemical stress.

A KEGG pathway analysis was also conducted to explore the significance of the putative targets. Among the top 20 signaling pathways as identified using *R* 4.1.0 (Fig. 11B) were the phosphoinositide 3-kinase (PI3K)-AKT signaling pathway, signaling pathways involving proteoglycans in cancer, and signaling pathways of importance to prostate cancer. A schematic diagram of the PI3K-AKT signaling pathway is shown in Fig. 11C.

### 3.3 Molecular docking of active components with potential targets

*In silico* molecular docking analyses were performed in order to further investigate the interactions between SFA compounds and the potential targets of SFA in the treatment of UC. In receptor-ligand docking analyses, more highly negative changes in free energy indicate stronger binding. As shown in Fig. 12, in the present study, the protein-compound pairs that exhibited the strongest binding were protein kinase C alpha (PRKCA) with isoxanthohumol, integrin beta 3 with trifolrhizin, PRKCA with trifolrhizin, the p110 $\alpha$  subunit of PI3K with trifolrhizin, and PRKCA with formononetin. The binding energies were less than  $-9$  kcal mol<sup>-1</sup>. The structures that resulted from the docking of each of the five receptor-ligand pairs were visualized using Discovery studio (Fig. 13).

### 3.4 Molecular dynamics simulations

Molecular dynamics simulation was utilized to ascertain the binding capabilities of small molecule compounds with key target proteins exhibiting optimal binding in molecular docking. Isoxanthohumol and PRKCA were selected for molecular dynamics simulations, given they demonstrated the strongest binding force in molecular docking procedures. The stability of the simulation system was assessed using root mean square deviation (RMSD). As shown in Fig. 14a, the complex system reaches equilibrium after 40 ns, and finally fluctuates around 3.3 Å. This indicates that the small molecule demonstrates high stability when bound to the target protein. Further analysis revealed that the composite system exhibited an initial upward trend from 60 ns to 95 ns, followed by a decline that gradually stabilized. This indicates that the composite system initially expanded, then contracted during the simulation process, ultimately achieving a stable state (Fig. 14b). Solvent Accessible Surface Area (SASA) serves as an important metric for assessing the surface area of a protein. In this simulation, the SASA was calculated for the interaction between the target protein and the small molecule (Fig. 14c). The results indicated that the complex system exhibited minor fluctuations during movement, eventually stabilizing over time. This suggests that the binding of small molecules influences the binding microenvironment, resulting in notable changes in SASA. The number of hydrogen bonds formed between the small molecule and the target protein during the dynamic process ranges from 0 to 4. In most instances, the complex system exhibits approximately 2 hydrogen bonds, suggesting that it has favorable hydrogen bond interactions (Fig. 14d). The Root mean square fluctuation (RMSF) value of the (Fig. 14e).

### 3.5 *In vitro* cell experiments

**3.5.1 Cell viability assay.** The CCK-8 assay results revealed that matrine, oxymatrine, sophoridine, formononetin, and kushenol I at concentrations of 50, and 150  $\mu$ mol  $\cdot$  L<sup>-1</sup> exhibited certain proliferative effects on RAW264.7 cells viability ( $P < 0.05$  or  $P < 0.01$ ). Subsequently, a concentration of 50  $\mu$ mol  $\cdot$  L<sup>-1</sup> of each compound was selected for further experiments (Fig. 15).






Fig. 10 Venn diagram of overlapping genes between compound and UC-related genes (A), compound-target network (B), and PPI network of SFA against UC (C).


**3.5.2 Anti inflammatory activity testing.** In comparison to the control group, the concentration of the pro-inflammatory factor IL-6 in RAW264.7 cells significantly increased after 24 h

of LPS treatment ( $P < 0.01$ ). Conversely, the mass concentration of the anti-inflammatory factor IL-10 significantly decreased ( $P < 0.01$ ). Following treatment with five compounds, the



concentration of cellular IL-6 was significantly lower than that observed in the model group, while the concentration of cellular IL-10 was significantly higher than that of the model group (Fig. 16).

UC is a non-specific, chronic, recurrent, and inflammatory disease of the intestinal tract. Its pathogenesis involves the destruction of the intestinal mucosal barrier, resulting in abnormalities in the stability and gut microbiota of the colon; these changes lead to activation of macrophages and T cells,








Fig. 14 Molecular dynamics simulation between isoxanthohumol and PRKCA. (a) RMSD. (b) Rg. (c) SASA. (d) HBond Numbers. (e) RMSF.

further altering the levels of immune-related cytokines and inducing a series of inflammatory reactions.<sup>12,13</sup>

Currently, the most commonly used drugs for the treatment of UC derive from Western medicine, including aminosalicylates, corticosteroids, and immunosuppressants. However, these drugs are often accompanied by adverse reactions, making the discovery of safe and effective drugs to prevent and treat UC an important research goal. Notably, TCM may have advantages in treating UC, though the complexity of the chemical components in such medicinal preparations means that the material basis for TCM action and its molecular mechanisms often remain unclear. In this study, UPLC-Q-TOF-MS/MS was employed to identify the chemical components of SFA and its processed products, and its key targets and pharmacodynamic mechanisms in the treatment of UC were analyzed using network pharmacology and molecular docking techniques, providing a reference for elucidating the mechanisms underlying the efficacy of SFA.

In previous studies, SFA was found to be able to treat UC, and the processed products showed more significant therapeutic effects. Still, the pharmacological material basis has yet to be thoroughly explored, and the specific mechanisms of action in its prevention and treatment of UC have yet to be elucidated. Here, UPLC-Q-TOF-MS/MS combined with network pharmacology allowed us to identify 159 potential targets of SFA in the treatment of UC, including epidermal growth factor receptor (EGFR), the protein-tyrosine kinase SRC, PIK3CA, and heat shock protein 90 alpha (HSP90α).

Pathways related to these targets have been associated with UC development. For example, the EGFR signaling pathway alters the rates of apoptosis and proliferation, and its activity is involved in the occurrence of colon mucosal injury. Damage to the intestinal mucosa in ulcerative colitis has been shown to

affect the expression of EGFR, thereby reducing its protective and reparative effects on the colon mucosa. Accordingly, EGFR levels have been found to correlate closely with UC recurrence. Therefore, the EGFR signaling pathway is a potential target in the treatment of UC.<sup>14,15</sup> Similarly, HSP90α is closely linked with inflammation, and inhibiting the expression of HSP90 can alleviate the inflammatory response. HSP90α is known to regulate the activation of inflammasomes and the secretion of interleukin (IL) 1β via its interactions with NLR family pyrin domain containing 3 (NLRP3).<sup>16</sup>

Inflammation serves as a defensive response of the organism to injury, infection, or other harmful stimuli, characterized by a dynamic equilibrium between pro-inflammatory and anti-inflammatory factors. Pro-inflammatory factors initiate and amplify the inflammatory response, while anti-inflammatory factors suppress inflammation and facilitate tissue repair. An imbalance between these two types of factors can lead to excessive or persistent inflammatory responses, potentially resulting in disease. PRKCA, a serine/threonine-specific protein kinase, plays a pivotal role in cellular signaling and regulates various biological processes, including cell proliferation, differentiation, and survival. The role of PRKCA in inflammation has been extensively studied. Research indicates that PRKCA is also crucial in modulating the production of reactive oxygen species (ROS), which are key mediators in numerous inflammatory responses. By inhibiting ROS production, PRKCA can alleviate cellular oxidative stress, thereby mitigating the inflammatory response.<sup>17</sup> Furthermore, the activation of PRKCA has been shown to suppress LPS-induced inflammatory responses, reducing the release of pro-inflammatory cytokines.<sup>18</sup> This reduction in pro-inflammatory cytokine release can, to some extent, upregulate anti-inflammatory factors, thereby inhibiting the onset of inflammation.

The active ingredients of SFA for the treatment of UC were identified through a joint analysis of components and targets. These ingredients mainly include alkaloids and flavonoids, including matrine, oxymatrine, formononetin, and kushenol I. Among the alkaloids, oxymatrine has been determined to be one of the main active ingredients of SFA, as it exhibits a wide range of pharmacological effects. It exerts therapeutic effects on organ fibrosis, protective effects on myocardial ischemia and infarction, and anti-inflammatory, antiviral, bactericidal, and anti-tumor effects.<sup>19</sup> Sophocarpine also has been demonstrated to have strong anti-inflammatory and analgesic effects, which may be related to calcium and inhibition of the secretion of inflammatory factors.<sup>20</sup>

The flavonoids in SFA have also been demonstrated to exert anti-inflammatory effects through interactions with modulation of NF-κB and other related pathways, which lead to inhibition of the expression of inflammatory factors.<sup>21</sup> Sophoraflavanone G can inhibit the neuroinflammation of lipopolysaccharide-activated microglia by regulating mitogen-activated protein kinases (MAPKs) and a signaling pathway involving nuclear factor erythroid 2-related factor and heme oxygenase-1.<sup>22</sup> Kushenol F can inhibit the production of IL-1 by inhibiting the activation of PI3K, AKT, and the p38 MAPK proteins β, IL-6, and tumor necrosis factor α. The inhibition of release of pro-






Fig. 15 Effects of matrine, oxymatrine, sophoridine, formononetin, and kushenol I on cells viability. \*\* $P < 0.01$  and \* $P < 0.05$  vs. control, mean  $\pm$  SD,  $N = 3$ .




Fig. 16 The effects of five active ingredients in SFA on pro-inflammatory cytokines and anti-inflammatory cytokines (including IL-6 and IL-10). \*\* $P < 0.01$  vs. control, ## $P < 0.01$  vs. model, mean  $\pm$  SD,  $N = 3$ .

inflammatory factors promotes, the secretion of anti-inflammatory factor IL-10, reduces inflammation damage to colon tissue, and thus improves related symptoms in UC mice.<sup>23</sup>

Based on the previous work suggesting the effectiveness of SFA components in inflammatory diseases, we conducted *in silico* analyses of molecular docking between the active ingredients of SFA and core targets in UC. The results showed that although each of the components was predicted to interact with each target, the binding affinities were different due to their different structures. The wide breadth of binding activities means that the active ingredients of SFA may synergistically act on multiple protein targets and signaling pathways to exert its anti-inflammatory effects. However, after processing, the degree of the therapeutic effect may change due to changes in chemical composition.

## 5. Conclusions

We determined that the active compounds of SFA act on multiple core targets, including EGFR, SRC, PIK3CA, and HSP90AA1, and they regulate multiple signaling pathways, including PI3K/AKT, lipid and atherosclerosis, and

proteoglycans in cancer. Thus, by combining the characterization of chemical composition with network pharmacology, the mechanisms of action of SFA in the treatment of UC were determined to involve multiple targets, multiple components, and multiple paths. This information also provides a reference for clinical medication. However, the reasons for the increased efficacy after processing still need to be clarified.

## Abbreviations

|                  |                                                                                     |
|------------------|-------------------------------------------------------------------------------------|
| TCM              | Traditional Chinese medicine                                                        |
| RSFA             | <i>Sophora flavescens</i> Ait processed with rice-washed water                      |
| WSFA             | <i>Sophora flavescens</i> Ait processed with wheat bran                             |
| SFA              | <i>Sophora flavescens</i> Ait                                                       |
| UPLC-Q-TOF-MS/MS | Ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry |
| UC               | Ulcerative colitis                                                                  |
| ESI              | Electrospray ionization                                                             |
| BP               | Biological process                                                                  |

|     |                        |
|-----|------------------------|
| MF  | Molecular function     |
| CC  | Cellular component     |
| TIC | Total ion chromatogram |

## Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

## Conflicts of interest

The authors declare no conflicts of interest.

## Acknowledgements

This research was supported by the Provincial Traditional Chinese Medicine Processing Technology Inheritance Base Project of the Liaoning Provincial Administration of Traditional Chinese Medicine (CCJDXM2020).

## References

- 1 D. G. Li, Q. Yang, Y. R. Cai, B. L. Li, D. Y. Zhao, P. L. Du, Y. X. Guo, T. Guo, B. T. Guo and X. M. Jia, Professor Li Diangui's Experience in the Treatment of Ulcerative Colitis with a Combination of Traditional Chinese and Western Medicine, *Chin. J. Integr. Tradit. West. Med. Dig.*, 2019, 27(04), 244–246.
- 2 Y. Q. An and H. J. Wang, Research progress on the distribution of Traditional Chinese Medicine syndrome and its correlation with enteroscopy in ulcerative colitis, *Chin. J. Integr. Tradit. West. Med. Dig.*, 2021, 29(05), 373–376.
- 3 T. H. Zhang and H. Shen, Ulcerative colitis and its TCM pattern-differentiation classification and inflammatory activity indexes: a correlation analysis, *J. Beijing Univ. Tradit. Chin. Med.*, 2019, 42(08), 685–690.
- 4 N. Li and L. Y. Zhong, *Processing Of Chinese Materia Medica*, China Medical Science Press, 2020, pp. 57–58.
- 5 G. R. Ding, *Summary Of Medicinal Properties*, 1917, pp. 19–20.
- 6 Chinese Pharmacopoeia Commission, *Pharmacopoeia Of The People's Republic Of China*, China Medical Science and Technology Press, Beijing, 2020, vol. I, pp. 211.
- 7 Y. Liu, L. Q. Shan and H. Gao, Comparison of the effects of water extract of *Sophora flavescens* Ait and its different processed products on dextran sulfate induced ulcerative colitis in mice, *Chin. Tradit. Pat. Med.*, 2021, 43(05), 1323–1328.
- 8 X. L. Pei, T. N. Jiang, Y. Liu and H. Gao, Regulatory effects of *Sophora flavescens* and its processed products on TLR4/MyD88/NF- $\kappa$ B signaling pathway in mice with damp-heat Ulcerative Colitis, *Chin. Arch. Tradit. Chin. Med.*, 2023, 1–11.
- 9 L. Mouad, H. El-Idrissi, S. Taoufiq, I. Bouchaib, N. Saffaj, R. Mamouni and Y. Kandri Rodi, QSAR modeling, molecular docking and molecular dynamic simulation of phosphorus-substituted quinoline derivatives as topoisomerase I inhibitors, *Arabian J. Chem.*, 2023, 16(6), 104783–104783.
- 10 M. Lahyaoui, A. Diane, H. El-Idrissi, T. Saffaj, Y. K. Rodi and B. Ihssane, QSAR modeling and molecular docking studies of 2-oxo-1, 2-dihydroquinoline-4- carboxylic acid derivatives as p-glycoprotein inhibitors for combating cancer multidrug resistance, *Heliyon*, 2023, 9(1), e13020, DOI: [10.1016/j.heliyon.2023.e13020](https://doi.org/10.1016/j.heliyon.2023.e13020).
- 11 Y. Q. Zhang and Q. F. Gong, Research on the ancient and modern application of rice swill in the processing of traditional Chinese medicine, *J. Tradit. Chin. Med. Sci.*, 2011, 42(04), 64–66.
- 12 B. Chassaing, J. D. Aitken, M. Malleshappa and M. Vijay-Kumar, Dextran sulfate sodium (DSS)-induced colitis in mice, *Curr. Protoc. Immunol.*, 2014, 104, 15, DOI: [10.1002/0471142735.im1525s104](https://doi.org/10.1002/0471142735.im1525s104).
- 13 R. Toumi, I. Soufli, H. Rafa, M. Belkhef, A. Biad and C. Touil-Boukoffa, Probiotic bacteria lactobacillus and bifidobacterium attenuate inflammation in dextran sulfate sodium-induced experimental colitis in mice, *Int. J. Immunopathol. Pharmacol.*, 2014, 27(4), 615–627, DOI: [10.1177/039463201402700418](https://doi.org/10.1177/039463201402700418).
- 14 P. Y. Chen, C. Yuan, Z. C. Hong, Y. Zhang, X. G. Ke, B. Yu, C. Wang, X. C. Xiao, H. Z. Wu and Y. F. Yang, Revealing the mechanism of “Huai Hua San” in the treatment of ulcerative colitis based on network pharmacology and experimental study, *J. Ethnopharmacol.*, 2021, 281, 114321, DOI: [10.1016/j.jep.2021.114321](https://doi.org/10.1016/j.jep.2021.114321).
- 15 T. He, W. Wang, L. Li, S. L. Qiu, S. M. Sun and L. Zong, PCNA, EGFR, MUC2 expression levels and clinical significance in ulcerative colitis, *J. Med. Res.*, 2022, 51(03), 104–107.
- 16 M. Zhang, L. Liu, X. Lin, Y. Wang, Y. Li, Q. Guo, S. Li, Y. Sun, X. Tao, D. Zhang, X. Lv, L. Zheng and L. Ge, A Translocation Pathway for Vesicle-Mediated Unconventional Protein Secretion, *Cell*, 2020, 181(3), 637–652.e15, DOI: [10.1016/j.cell.2020.03.031](https://doi.org/10.1016/j.cell.2020.03.031).
- 17 Q. J. Zhu, J. Wang, Y. Li, Z. J. Bai, X. B. Guo and T. Pan, PRKCA Promotes Mitophagy through the miR-15a-5p/PDK4 Axis to Relieve Sepsis-Induced Acute Lung Injury, *Infect. Immun.*, 2023, 91(1), e0046522, DOI: [10.1128/iai.00465-22](https://doi.org/10.1128/iai.00465-22).
- 18 M. Wang, H. Zhong, X. Zhang, X. Huang, J. Wang, Z. Li, M. Chen and Z. Xiao, EGCG promotes PRKCA expression to alleviate LPS-induced acute lung injury and inflammatory response, *Sci. Rep.*, 2021, 11(1), 11014, DOI: [10.1038/s41598-021-90398-x](https://doi.org/10.1038/s41598-021-90398-x).
- 19 X. Lan, J. Zhao, Y. Zhang, Y. Chen, Y. Liu and F. Xu, Oxymatrine exerts organ- and tissue-protective effects by regulating inflammation, oxidative stress, apoptosis, and fibrosis: From bench to bedside, *Pharmacol. Res.*, 2020, 151, 104541, DOI: [10.1016/j.phrs.2019.104541](https://doi.org/10.1016/j.phrs.2019.104541).
- 20 F. L. Wang, H. Wang, J. H. Wang, D. X. Wang, Y. Gao, B. Yang, H. J. Yang, Y. B. Ji and G. S. Xin, Analgesic and Anti-Inflammatory Activities of Sophocarpine from *Sophora viciifolia* Hance, *BioMed Res. Int.*, 2021, 2021, 8893563, DOI: [10.1155/2021/8893563](https://doi.org/10.1155/2021/8893563).

- 21 X. D. He, Z. Y. Fu, Y. Huang, J. B. He, X. M. Pu, J. Li, Y. J. Li, J. Yu and X. X. Yang, Research progress on the chemistry and bioactivity of isopentenyl flavonoids from *Sophora flavescens*, *Chin. J. Clin. Pharmacol. Ther.*, 2022, 27(08), 899–907.
- 22 C. Guo, L. Yang, C. X. Wan, Y. Z. Xia, C. Zhang, M. H. Chen, Z. D. Wang, Z. R. Li, X. M. Li, Y. D. Geng and L. Y. Kong, Anti-neuroinflammatory effect of Sophoraflavanone G from *Sophora alopecuroides* in LPS-activated BV2 microglia by MAPK, JAK/STAT and Nrf2/HO-1 signaling pathways, *Phytomedicine*, 2016, 23(13), 1629–1637, DOI: [10.1016/j.phymed.2016.10.007](https://doi.org/10.1016/j.phymed.2016.10.007).
- 23 X. D. He, H. Y. Ni, J. B. He, M. Li, Y. K. Hu, D. H. Gong, J. L. Yao, J. Yu and X. X. Yang, Intervention effect of kushenol F on ulcerative colitis mice, *China Pharm.*, 2024, 35(04), 419–424.